Revenue Performance - Revenues for the three-month period ended February 29, 2024, increased by 33to45, compared to 12forthesameperiodin2023,drivenbyinitialdeliveriesofLoop™PETresin[221].−ForthefiscalyearendedFebruary29,2024,revenuesdecreasedby20 to 153,comparedto173 for the same period in 2023, attributed to initial deliveries of Loop™ PET resin [227]. - Revenue for the year ended February 29, 2024, was 153,000,adecreaseof11.6173,000 for the year ended February 28, 2023 [287]. Net Loss and Financial Performance - The net loss for the three-month period ended February 29, 2024, increased by 10,514to5,091, compared to a net income of 5,423forthesameperiodin2023,largelyduetoapriorgainonlanddispositionof9,980 [224]. - The net loss for the year ended February 29, 2024, decreased by 214to21,087, compared to 21,301forthesameperiodin2023[230].−TheCompanyincurredanetlossof21.1 million for the year ended February 29, 2024, with net cash flows used from operating activities amounting to 18.0million[276].−Comprehensivelossdecreasedto21,016,000 from 22,346,000,reflectinga5.90.44, compared to 0.45inthepreviousyear,indicatingaminorimprovement[287].ResearchandDevelopmentExpenses−Researchanddevelopmentexpensesforthethree−monthperiodendedFebruary29,2024,roseby805 to 3,018,primarilyduetoan866 increase in plant and laboratory operating expenses, including an inventory write-down of 817[222].−TotalresearchanddevelopmentexpensesforthefiscalyearendedFebruary29,2024,were11,379, a decrease of 5,967fromthepreviousyear[226].−Researchanddevelopmentexpensesdecreasedby5,967 to 11,379fortheyearendedFebruary29,2024,comparedto17,346 for the same period in 2023 [228]. - Research and development expenses primarily relate to process development, customer trials, and testing of pre-production samples, and are presented net of related tax credits and government grants [313]. Cash Flow and Liquidity - Cash and cash equivalents on hand were 6,958asofFebruary29,2024,withanundrawnseniorloanfacilityof2,579 [230]. - Net cash used in operating activities was 18,034fortheyearendedFebruary29,2024,comparedto34,892 for the year ended February 28, 2023 [244]. - The company has incurred net losses and negative cash flow from operating and investing activities since its inception, with no material revenues from customers [302]. - Management estimates that current available liquidity and forecasted net cash flows will not be sufficient to meet the company's obligations over the next twelve months [303]. - As of February 29, 2024, the Company's available liquidity was 9.5million,consistingofcashandcashequivalentsof6.9 million and an undrawn senior loan facility of 2.6million[276].GeneralandAdministrativeExpenses−Generalandadministrativeexpensesforthethree−monthperiodendedFebruary29,2024,increasedby22 to 2,221,primarilyduetoanincreaseinstock−basedcompensation[223].−Generalandadministrativeexpensesdecreasedby10,441 to 9,988fortheyearendedFebruary29,2024,comparedto20,429 for the same period in 2023 [229]. - General and administrative expenses for the year ended February 29, 2024 were 9,988,000,down51.120,429,000 in the prior year [390]. Debt and Financing - The company is pursuing financing for its planned manufacturing facilities, which is critical for moving to the next stage of strategic development [218]. - The Company has a long-term debt obligation of up to 3,390relatedtotheexpansionoftheTerrebonneFacility,withrepaymentsstructuredover72monthlyinstallments[234].−Thecompanyisseekingtofinalizenegotiationsforpreviouslyannouncedfinancinginitiativesonacceptableterms[232].−Totalrepaymentsdueonthecompany′sindebtednessoverthenextfiveyearsamountto3,511 [371]. - Interest expense on the Investissement Québec loan for the year ended February 29, 2024, was 84,comparedto86 in 2023 [366]. Inventory and Assets - The company reported total inventories of 102,000asofFebruary29,2024,adecreasefrom727,000 in the previous year, with an allowance for inventory write-down of 817,000recorded[343].−Thetotalcurrentassetsdecreasedfrom36.4 million as of February 28, 2023, to 8.0millionasofFebruary29,2024[282].−Thetotalstockholders′equitydecreasedfrom33.7 million as of February 28, 2023, to 14.1millionasofFebruary29,2024[284].StrategicDevelopments−AstrategicpartnershipwithEsterwasannouncedtobuildanInfiniteLoop™manufacturingfacilityinIndia,expectedtocommencecommercialoperationsinearly2027[212].−TheplannedfacilityinUlsan,SouthKorea,isexpectedtosupplyupto70,000metrictonsperyearofLoop™PETresin,withconstructiontimingcurrentlyunderreview[215].−Thecompanyintendstocontinueexecutingitscorporatestrategy,focusingoncommercializationofInfiniteLoop™Technologyandsecuringfinancingforoperationsandprojects[248].Stock−BasedCompensation−Stock−basedcompensationexpenseswere1,422,000, significantly lower than 10,086,000inthepreviousyear[294].−Stock−basedcompensationattributabletostockoptionsfortheyearendedFebruary29,2024amountedto644,000, compared to 1,316,000in2023[393].−Stock−basedcompensationattributabletoRSUsfortheyearendedFebruary29,2024,amountedto778, a significant decrease from $8,770 in 2023 [396]. - The total number of outstanding restricted stock units (RSUs) at the end of 2024 was 4,368,897, compared to 3,888,618 at the end of 2023, reflecting an increase of approximately 12.3% [395].